Novel nutraceutical supplements with yeast beta-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial

Imagem de Miniatura
Arquivos
art_NEHMI-FILHO_Novel_nutraceutical_supplements_with_yeast_betaglucan_prebiotics_minerals_.PDF (1.72 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
NEHMI-FILHO, Victor
SANTAMARINA, Aline Boveto
PALACE-BERL, Fanny
SOUZA, Erica de
MIRANDA, Danielle Araujo de
Citação
FRONTIERS IN ENDOCRINOLOGY, v.13, article ID 1089938, 11p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
PurposeIt is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters. MethodsSedentary volunteers (women and men) with body mass index (BMI) <= 34.9 kg/m(2) were divided into two groups: Novel Nutraceutical Supplement_(S) (n = 30) and Novel Nutraceutical Supplement (n = 29), differing in the absence (S) or presence of silymarin, respectively. Volunteers were instructed to take two capsules in the morning and two capsules in the evening. No nutritional intervention was performed during the study period. The data (anthropometrics and anamneses) and harvest blood (biochemistry and hormonal exams) were collected at three different time points: baseline time [day 0 (T0)], day 90 (T90), and day 180 (T180) post-supplementation. ResultsIn the anthropometric analysis, the waist circumference in middle abdomen (WC-mid) and waist circumference in iliac crest (WC-IC) were reduced. Also, the waist-to-height ratio (WHt R) and waist-to-hip ratio (WHR) seem to slightly decrease alongside the supplementation period with both nutraceutical supplements tested as well as transaminase enzyme ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)], a known as a biomarker of NAFLD, and endocrine hormones cortisol and thyroid-stimulating hormone (TSH) at 90 and 180 days post-supplementation. ConclusionsIn a condition associated with sedentary and no nutritional intervention, the new nutraceutical supplement composition demonstrated the ability to be a strong and newfangled tool to improve important biomarkers associated with obesity and its comorbidities.
Palavras-chave
nutraceutics, supplement, Silybum marianum, prebiotic, obesity, endocrine parameters, transaminases
URI
https://observatorio.fm.usp.br/handle/OPI/52821
Referências
  1. Abenavoli L, 2018, PHYTOTHER RES, V32, P2202, DOI 10.1002/ptr.6171
  2. Abou Nehmi V, 2021, J INTEGR MED-JIM, V19, P439, DOI 10.1016/j.joim.2021.05.002
  3. Akbari M, 2018, INFLAMMOPHARMACOLOGY, V26, P685, DOI 10.1007/s10787-018-0458-0
  4. Andrade EF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8120792
  5. Avery JC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091203
  6. Banach W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197306
  7. Burton-Freeman BM, 2016, ADV NUTR, V7, P44, DOI 10.3945/an.115.009639
  8. Byrne CD, 2013, P NUTR SOC, V72, P412, DOI 10.1017/S0029665113001249
  9. Calder PC, 2011, BRIT J NUTR, V106, pS1, DOI 10.1017/S0007114511005460
  10. Cao Y, 2016, MOL NUTR FOOD RES, V60, P2678, DOI 10.1002/mnfr.201600032
  11. Cena H, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020334
  12. Chen LX, 2016, INT IMMUNOPHARMACOL, V37, P65, DOI 10.1016/j.intimp.2016.02.005
  13. Costa GT, 2012, ACTA CIR BRAS, V27, P279, DOI 10.1590/S0102-86502012000300013
  14. Darnton-Hill I, 2004, PUBLIC HEALTH NUTR, V7, P101, DOI 10.1079/PHN2003584
  15. Dragano NRV, 2013, BRIT J NUTR, V110, P447, DOI 10.1017/S0007114512005090
  16. Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
  17. Fernandez-Sanchez A, 2011, INT J MOL SCI, V12, P3117, DOI 10.3390/ijms12053117
  18. Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
  19. Han TS, 2016, JRSM CARDIOVASC DIS, V5, DOI 10.1177/2048004016633371
  20. Hashmi A, 2016, PROBIOTICS ANTIMICRO, V8, P19, DOI 10.1007/s12602-016-9206-1
  21. Haun DR, 2009, REV ASSOC MED BRAS, V55, P705, DOI 10.1590/S0104-42302009000600015
  22. Heyman L, 2014, J NUTR METAB, V2014, DOI 10.1155/2014/403041
  23. Iossa S, 2003, BRIT J NUTR, V90, P953, DOI 10.1079/BJN2003000968
  24. Jamar G, 2013, INT J CLIN PRACT, V67, P217, DOI 10.1111/ijcp.12041
  25. Jean-Louis G, 2020, DIABET METAB SYND OB, V13, P3471, DOI 10.2147/DMSO.S267952
  26. Kim J, 2014, BIOL TRACE ELEM RES, V157, P101, DOI 10.1007/s12011-013-9885-3
  27. Konstantinidi Melina, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6030094
  28. Lala V., 2022, STATPEARLS
  29. Liu FT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10722-2
  30. Lobato RV, 2015, NUTR HOSP, V32, P256, DOI 10.3305/nh.2015.32.1.9013
  31. MacDonald-Ramos K, 2021, ANN HEPATOL, V23, DOI 10.1016/j.aohep.2020.08.072
  32. Makhoul E, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.27438
  33. Matsudo S, 2001, REV BRAS ATIV FIS SA, V6, P5, DOI 10.12820/RBAFS.V.6N2P5-18
  34. Medina J, 2004, DIABETES CARE, V27, P2057, DOI 10.2337/diacare.27.8.2057
  35. Mullan A, 2016, ATHEROSCLEROSIS, V246, P169, DOI 10.1016/j.atherosclerosis.2016.01.004
  36. Negi CK, 2022, METABOLISM, V126, DOI 10.1016/j.metabol.2021.154925
  37. Nielsen FH, 2010, NUTR REV, V68, P333, DOI 10.1111/j.1753-4887.2010.00293.x
  38. Nogueira LD, 2017, J AM COLL NUTR, V36, P108, DOI 10.1080/07315724.2016.1194236
  39. Oliveira V, 2015, ENDOCRINOLOGY, V156, P4033, DOI 10.1210/en.2014-1880
  40. Qin BL, 2012, BRIT J NUTR, V108, P581, DOI 10.1017/S000711451100599X
  41. Rani V, 2016, LIFE SCI, V148, P183, DOI 10.1016/j.lfs.2016.02.002
  42. Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9
  43. Rief P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003843
  44. Rodrigues SL, 2010, ARQ BRAS CARDIOL, V95, P186, DOI 10.1590/S0066-782X2010005000073
  45. Rogero MM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040432
  46. Rosenzweig T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084193
  47. Rupasinghe HPV, 2016, PHARMACOL THERAPEUT, V165, P153, DOI 10.1016/j.pharmthera.2016.06.005
  48. Sabater-Molina M, 2009, J PHYSIOL BIOCHEM, V65, P315, DOI 10.1007/BF03180584
  49. Santamarina AB., 2022, PHYS REV LETT, V11, P1, DOI 10.3390/antiox11030447
  50. Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
  51. Schumann J, 2003, J HEPATOL, V39, P333, DOI 10.1016/S0168-8278(03)00239-3
  52. Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
  53. Stothers CL, 2021, J IMMUNOL, V207, P2785, DOI 10.4049/jimmunol.2100107
  54. Tahan V, 2008, HEPATO-GASTROENTEROL, V55, P1433
  55. Tarantino G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413424
  56. Thompson AL, 2015, J NUTR, V145, P1335, DOI 10.3945/jn.114.206102
  57. Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
  58. Torres DPM, 2010, COMPR REV FOOD SCI F, V9, P438, DOI 10.1111/j.1541-4337.2010.00119.x
  59. WHO, 2019, WHONMHPND20199
  60. Ye JP, 2013, FRONT MED-PRC, V7, P14, DOI 10.1007/s11684-013-0262-6

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Carregar mais